The Monday Brief — Week of Jul 15, 2026

Steel Partners, a major InMode shareholder, has launched an unsolicited takeover bid at $16.75 per share in cash, challenging a competing CEO-led buyout proposal. The move has triggered court filings to pause review of the original deal. InMode is expected to report Q2 earnings on August 5, with preliminary guidance of $95.2M–$95.4M in revenue and full-year 2026 guidance of $365M–$375M—solid numbers that may complicate any acquisition timeline. Watch the board's response and whether either bid gains traction; the outcome could reshape InMode's product roadmap and pricing strategy for practices using their platforms.

Medicare has formally entered price negotiations for Botox and 14 other drugs this year, signaling direct government pressure on neuromodulator costs. This is the opening salvo in a multi-year reckoning: prices will likely decline, but not immediately. Expect manufacturers to accelerate direct-to-practice marketing and bundled offerings to offset volume loss. Evolus is already moving aggressively, launching a Jeuveau Rewards program and securing exclusive U.S. rights to Profhilo (a skin-quality injectable from IBSA) to diversify its portfolio and compete on value. Monitor your supplier contracts closely—rebate structures and volume commitments may shift.

Cynosure Lutronic has launched its XERF monopolar RF platform in Europe and is accelerating adoption across North America, riding a wave of patient demand for non-invasive skin tightening. The company is positioning XERF as a leading monopolar RF option, competing directly with established players. Simultaneously, SkinStylus received new FDA clearance for periorbital wrinkles across all skin types, and Candela's Nordlys non-ablative fractional laser is gaining clinical credibility (new Nature study on epigenetic aging reversal). If you're evaluating RF or fractional laser equipment, this is prime time to negotiate—vendors are hungry for practice commitments.

The GLP-1 aesthetic care market is projected to reach $2 billion by 2030, driven by Ozempic/Wegovy adoption and the resulting demand for post-weight-loss body contouring. Practices like Blackhawk Plastic Surgery are already reporting surging interest in liposuction, skin tightening, and combination procedures. This trend is reshaping service mix and staffing: owners who bundle injectables, RF, and surgical offerings are capturing higher lifetime value per patient. If your practice hasn't mapped a GLP-1 body-contouring pathway, now is the time—patient volume is accelerating.

The neuromodulator space is crowded: seven FDA-approved options are now available or in late-stage review (including Galderma's Relabotulinum, which is progressing through U.S. regulatory review). Millennials are nearly matching Gen X in Botox adoption, expanding the addressable market but also fragmenting it. Daewoong Pharma's Nabota topped 1 trillion won in sales and is accelerating its global push. Expect continued price competition, loyalty programs, and direct-to-consumer marketing. Practices should audit their injectable supplier mix and negotiate volume-based pricing before Q4 budget cycles lock in.

L'Oréal has increased its stake in Galderma to 20%, signaling confidence in the dermatology and aesthetics play. This move underscores the strategic value of med-spa and aesthetic brands to luxury conglomerates. Sisram Medical is also restructuring its DAXXIFY China deal with a connected Fosun unit, reflecting ongoing consolidation in the botulinum toxin supply chain. These moves may eventually affect product availability, pricing, and marketing support for independent practices—stay alert to supply-chain announcements and distributor changes.

• August 5: InMode Q2 earnings call—listen for guidance updates and any M&A commentary.
• Takeover timeline: Court filings and board responses on the Steel Partners bid could move quickly; check investor relations for updates.
• Medicare negotiations: No immediate price cuts, but watch for manufacturer announcements on rebate programs and practice incentives.
• RF/laser vendor outreach: Expect aggressive pitches from Cynosure, Candela, and others—use this leverage to negotiate better terms on equipment and service contracts.
• GLP-1 referral partnerships: If you're not already connected to weight-loss clinics or primary-care practices, this is the week to build those relationships.